At ValidExamDumps, we consistently monitor updates to the SCDM CCDM exam questions by SCDM. Whenever our team identifies changes in the exam questions,exam objectives, exam focus areas or in exam requirements, We immediately update our exam questions for both PDF and online practice exams. This commitment ensures our customers always have access to the most current and accurate questions. By preparing with these up to date and 100% exam domain coverage questions, our customers can successfully pass the SCDM Certified Clinical Data Manager exam on their first attempt without needing additional materials or study guides.
Other certification materials providers often include outdated or removed questions by SCDM in their SCDM CCDM exam. These outdated questions lead to customers failing their SCDM Certified Clinical Data Manager exam. In contrast, we ensure our questions bank includes only precise and up-to-date questions. Our main priority is your success in the SCDM CCDM exam, not profiting from selling obsolete exam questions in PDF or Online Practice Test.
A relational database has tables for PATIENT_DEMOGRAPHY and VITAL_SIGNS data collected during a visit. The primary key for the VITAL_SIGNS table is a composite key that includes the unique patient identifier, visit number, and vital signs parameter name. The two tables are joined on the patient identifier. What will be the number of records in the result set?
In a relational database structure, each record in a table is uniquely identified by a primary key. In this case, the VITAL_SIGNS table uses a composite primary key consisting of:
Patient Identifier,
Visit Number, and
Vital Signs Parameter Name.
This means each record represents a unique measurement of a specific parameter (e.g., blood pressure, pulse) for a patient at a specific visit.
When joining PATIENT_DEMOGRAPHY and VITAL_SIGNS tables on the patient identifier, the result set will include one record for every combination of patient, visit, and parameter --- i.e., one record per patient per visit per vital sign parameter.
Therefore, option C correctly describes the expected number of records.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 5.2 -- Primary and Foreign Key Relationships in Relational Models
CDISC SDTM Implementation Guide, Section 5.3 -- Observation-Level Data Structures
ICH E6(R2) GCP, Section 5.5.3 -- Data Organization and Integration Principles
Which metrics report listed below would best help identify trends in the clinical data?
The Query frequency counts per data element (Option D) is the best metric for identifying data trends and potential systemic data issues in clinical trials.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Quality Assurance and Control), trend analysis involves identifying recurring data issues across subjects, sites, or variables to detect training gaps, protocol misinterpretation, or CRF design flaws. A high number of queries generated for specific fields (e.g., visit date, lab values, or dosing information) may indicate systemic problems such as unclear CRF instructions or site-level misunderstandings.
While metrics such as percent of data cleaned (A) and time to database lock (B) reflect overall progress and efficiency, they do not identify specific data pattern issues. The number of subjects screened/enrolled (C) pertains to recruitment rather than data quality.
Therefore, query frequency per data element provides actionable insights for quality improvement, process refinement, and early identification of potential risks.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 6.3 -- Metrics and Trend Analysis
ICH E6 (R2) Good Clinical Practice, Section 5.18.4 -- Risk-Based Quality Review and Data Trends
FDA Guidance for Industry: Oversight of Clinical Investigations -- Risk-Based Monitoring, Section 6 -- Data Metrics and Trend Evaluation
Which metric reveals the timeliness of the site-work dimension of site performance?
The site-work dimension of site performance evaluates how efficiently sites manage and resolve data-related tasks --- particularly query resolution, data entry, and correction timelines. Among the given metrics, the median and range of time from query generation to resolution (D) directly measures the site's responsiveness and data management efficiency.
According to the GCDMP (Chapter on Metrics and Performance Measurement), this indicator helps identify sites that delay query resolution, which can impact overall study timelines and data quality. Tracking this metric allows the data management team to proactively provide additional training or communication to underperforming sites.
Other options measure different aspects of project progress:
A reflects overall database closure speed.
B and C relate to study startup and enrollment readiness, not ongoing data work.
Thus, option D accurately represents a site performance timeliness metric, aligning with CCDM principles for operational performance measurement.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Metrics and Performance Management, Section 5.4 -- Site Query Resolution Metrics
ICH E6(R2) Good Clinical Practice, Section 5.18 -- Monitoring and Site Performance Oversight
ACME Intervention Co. is testing a new carotid artery stent in patients with coronary artery disease, in hopes of proving superiority over the current standard of care. After a subject signs consent, the surgeon enrolls the patient and retrieves information on which stent to use, but the surgeon does not share this information with the subject. Yesterday, the surgeon was instructed to use the control stent. Today, the surgeon has completed two surgeries: the first one the surgeon was instructed to use the control stent; the second one the surgeon was instructed to use the test stent. In what type of trial is the surgeon participating?
This scenario describes a single-blind trial, in which only one party---typically the subject---is unaware of the treatment assignment, while the investigator or surgeon knows which intervention is being administered.
In this case, the surgeon receives instructions on which stent (test or control) to use, meaning they are aware of treatment allocation. However, the subject is blinded to which device is being implanted. This setup minimizes subject bias while maintaining procedural safety since the surgeon must know which product to use.
Double-blind (A): Neither subject nor investigator knows the treatment.
Open-label (B): Both subject and investigator know the treatment.
Cross-over (D): Each subject receives both treatments in different periods.
Thus, the correct answer is C. Single-blind, as only the participant remains blinded in this surgical device trial design.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Clinical Trial Phases and Protocols, Section 3.2 -- Study Blinding and Randomization Concepts
ICH E6(R2) GCP, Section 1.10 -- Definition of Blinding/Masking
FDA Guidance for Industry: Design Considerations for Pivotal Clinical Investigations for Medical Devices, Section 5.3 -- Blinding in Device Studies
A study takes body-composition measurements at baseline using a DEXA scanner. Which information is needed to correctly associate the body-composition data to the rest of the study data?
To properly associate body-composition data (from a DEXA scanner) with other study data, both the subject number and the visit number are required.
According to the GCDMP (Chapter: Data Management Planning and Study Start-up), every clinical data record must be uniquely identifiable and linkable to a specific subject and study event. The subject number identifies the participant, while the visit number defines the temporal context in which the measurement was taken.
Without both identifiers, data integration becomes ambiguous---especially if multiple assessments occur over time (e.g., baseline, week 12, end of study). Including both ensures data traceability, integrity, and alignment with the protocol-defined schedule of events.
Study number (option A) alone does not distinguish between visits or subjects, and visit number alone (option C) lacks linkage to the individual participant.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 4.4 -- Data Linking and Identification Requirements
ICH E6 (R2) GCP, Section 5.5.3 -- Data Traceability Principles
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations -- Data Identification Requirements
